CIHR is a partner in the upcoming TRANSCAN-3 Joint Transnational Call (JTC) 2024: “Combination therapies against cancer: New opportunities for translational research”. TRANSCAN-3 JTC 2024 is an international funding opportunity focused on high-impact translational cancer research with anticipated 21 partners from 16 countries. The main purpose of this call will be design of patient preclinical… Read more »
CIHR-IG is pleased to be partnering with the Fonds de recherche du Québec – Santé (FRQS), Ataxia Canada and approximately 26 international funding organizations in the context of this European Joint Programme on Rare Diseases (EJP RD) call for proposals 2022. CIHR-IG is committed to expanding and improving the diagnosis and treatment of rare diseases by creating the conditions needed to… Read more »
CIHR-IG is pleased to be partnering with the Fonds de recherche du Québec – Santé (FRQS), Ataxia Canada and approximately 26 international funding organizations in the context of this European Joint Programme on Rare Diseases (EJP RD) call for proposals 2022. CIHR-IG is committed to expanding and improving the diagnosis and treatment of rare diseases by creating the conditions needed to… Read more »
It is estimated that 55 million deaths occurred in the world in 2017, of which 1 7.7 million were from cardiovascular disease. Each year, cardiovascular diseases (CVD) cause 3.9 million deaths in the European continent and over 1.8 million deaths in the European Union (EU). Furthermore, these diseases are one of the leading causes of… Read more »
